



Result of AGM

December 17, 2021

RNS Number : 0925W

Renalytix PLC

17 December 2021

Renalytix plc ("Renalytix" or the "Company")

Result of AGM

LONDON and SALT LAKE, 17 December 2021 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The results of the AGM are detailed below:

Resolution	In Favour Votes	%	Against Votes	%	Withheld Votes
1	36,309,096	99.95%	16,442	0.05%	40,498
2	25,272,488	70.34%	10,658,539	29.66%	26,932
3	27,437,320	76.36%	8,493,707	23.64%	26,932
4	36,289,799	99.81%	67,343	0.19%	8,894
5	36,339,057	99.95%	18,085	0.05%	8,894
6	36,337,208	99.95%	16,694	0.05%	12,134
7	36,339,655	99.95%	17,268	0.05%	9,113
8	35,826,173	98.54%	529,873	1.46%	9,990
9	27,776,213	77.27%	8,170,453	22.73%	11,293
10	35,891,613	99.94%	21,157	0.06%	45,189

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)
Alex Price / Nicholas Moore

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams

Tel: 020 7597 4000

Walbrook PR Limited
Paul McManus / Lianne Applegarth

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303

About KidneyIntelX

KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGBUBDDSXBDGBR